D-0097-2018 Class III Terminated

Recalled by Lupin Pharmaceuticals Inc. — Baltimore, MD

FDA drug recall D-0097-2018 was initiated by Lupin Pharmaceuticals Inc. on Nov 21, 2017 and is designated Class III. Reason for recall: Failed Dissolution Specification The recall status is terminated (terminated Apr 15, 2019). Affected quantity: 111,648 units.

Recall details

Product Type
Drugs
Report Date
Dec 6, 2017
Initiation Date
Nov 21, 2017
Termination Date
Apr 15, 2019
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
111,648 units

Product description

Duloxetine Delayed-Release Capsules USP, 30 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited Goa 403 722 India, NDC 68180-295-06, UPC 368180295068

Reason for recall

Failed Dissolution Specification

Distribution pattern

Nationwide within the United States

Code information

Lot #: G602051, Exp. 12/2017

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0097-2018
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0097-2018. Report a data issue: hello@regdatalab.com.